Big Pharma Pushes Watson's Oxytrol To Specialty Area
This article was originally published in The Pink Sheet Daily
Continued decline in sales of the overactive bladder patch reinforces Watson focus on the urologist specialty area; firm cites inadequate resources to compete with big pharma in the primary care market.
You may also be interested in...
The company has initiated an internal and external search to fill the new positions. As part of the reorganization, Watson President and COO Joseph Papa is leaving the company Nov. 19.
The company is seeking a partner with "strong relationships" with high-volume prescribers of overactive bladder therapies in the primary care market. Watson wants to retain Oxytrol's position in primary care despite the company's intention to shift its marketing focus to specialty care.
Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue